Response to letter regarding "cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy"

American Journal of Transplantation

Volumn 12, Issue 10, 2012, Pages 2859-2860

  Atabani, S F ^a   Emery, V C ^a   Smith, C ^a   Harber, M ^a   Thorburn, D ^a   Griffiths, P D ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR; VIRUS DNA;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG TREATMENT FAILURE; GRAFT RECIPIENT; HEPATITIS; HUMAN; INFECTION RISK; LETTER; LIVER TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT RESPONSE; VIREMIA; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

CYTOMEGALOVIRUS INFECTIONS; HUMANS;

EID: 84867035711     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04227.x     Document Type: Letter

References (4)

1. Limaye AP,. Reasons for breakthrough CMV disease in patients who receive preemptive therapy. Am J Transplant 2012; 12: 2858.
2. Atabani SF, Smith C, Atkinson C, et al,. Cytomegalovirus replication kinetics in solid organ transplant recipients Managed by preemptive therapy. Am J Transplant 2012; 12: 2457-2464.
3. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
4. Humar A, Lebranchu Y, Vincenti F, et al,. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.